NCT06142279View on ClinicalTrials.gov

Development and Qualification of Methods for Analyzing the Mucosal Immune Response to COVID-19

NANot yet recruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2024

Conditions
Certain Disorders Involving the Immune Mechanism
Interventions
BIOLOGICAL

Sampling

At baseline, nasal, salivary and blood sampling will be taken for the participants.

BIOLOGICAL

PCR (polymerase chain reaction) SARS-CoV-2

At baseline, this PCR SARS-CoV-2 will be taken for the participants.

Trial Locations (1)

37044

CHRU de Tours, Tours

All Listed Sponsors
lead

University Hospital, Tours

OTHER

NCT06142279 - Development and Qualification of Methods for Analyzing the Mucosal Immune Response to COVID-19 | Biotech Hunter | Biotech Hunter